These derivatives were subsequently evaluated for their predicted binding affinities, drug-like properties, pharmacokinetic profiling, and toxicity prediction, to identify compounds with improved inhibitory potential against EZH2, and thus therapeutic relevance in PC. This evidence concerns the gene EZH2 and pachyonychia congenita.